PRES in the course of hemato-oncological treatment in children
Open Access
- 2 December 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Child's Nervous System
- Vol. 34 (4), 691-699
- https://doi.org/10.1007/s00381-017-3664-y
Abstract
Introduction Posterior reversible leukoencephalopathy syndrome (PRES) is a clinical syndrome of varying aetiologies, characterised by acute neurological symptoms of brain dysfunction with MRI abnormalities in posterior cerebral white and grey matter. In most cases, symptoms resolve without neurological consequences. Aim The aim of this paper is the analysis of predisposing factors, clinical outcomes and radiological features of PRES in eight children with hemato-oncological disease. Material and methods We analysed the medical records of eight hemato-oncological patients aged from 3.0 to 16.1 years. The mean of age at primary diagnosis was 8.5 years. Results All patients had both clinical and radiological PRES features. Seven out of eight underwent intensive chemotherapy regimens. Time elapsed from start of treatment to the occurrence of PRES ranged from 6 to 556 days. In one case, PRES occurred before chemotherapy and was the first symptom of cancer. Most (six of eight) patients had history of hypertension (> 95pc) and some (two of eight) occurred electrolyte imbalance—mainly hypomagnesaemia. Patients presented headache (seven of eight), disturbances of consciousness (six of eight), seizures (six of eight), visual changes (four of eight) and vomiting (three of eight). MRI demonstrated abnormalities in seven children: typical cerebral oedema in the white matter of the occipital to the parietal lobes. Most patient lesions in the MRI shrunk after 4 weeks, and clinical symptoms of PRES disappeared completely within a few hours to few days. Conclusion PRES may complicate oncological treatment in children. Hypertension is the most important risk factor of PRES. PRES should be included in differential diagnosis in all patients with acute neurological symptoms.This publication has 37 references indexed in Scilit:
- Status epilepticus as a main manifestation of posterior reversible encephalopathy syndrome after pediatric hematopoietic stem cell transplantationPediatric Blood & Cancer, 2011
- Isolated cerebellar involvement in posterior reversible encephalopathy syndrome in a child with acute lymphoblastic leukemiaIndian Journal of Medical and Paediatric Oncology, 2011
- Age and gender may affect posterior reversible encephalopathy syndrome in renal diseasePediatric Nephrology, 2011
- Posterior reversible encephalopathy syndrome in childhood cancerAnnals of Oncology, 2010
- Reversible posterior leukoencephalopathy syndrome in childhood: report of nine cases and review of the literatureNeurological Sciences, 2009
- A Case of Gemcitabine and Cisplatin Associated Posterior Reversible Encephalopathy SyndromeCancer Research and Treatment, 2009
- Posterior Reversible Encephalopathy Syndrome, Part 2: Controversies Surrounding Pathophysiology of Vasogenic EdemaAmerican Journal of Neuroradiology, 2008
- Reversible posterior leukoencephalopathy syndrome in children undergoing induction therapy for acute lymphoblastic leukemiaPediatric Blood & Cancer, 2007
- Posterior reversible encephalopathy syndrome in children with cancerPediatric Blood & Cancer, 2005
- Neuroimaging in Posterior Reversible Encephalopathy SyndromeJournal of Neuroimaging, 2004